Table 1.
Characteristics of the 47 reported in case series/reports.
| Parameter | Value | |
|---|---|---|
| Gender | Male | 33 (70.21%) |
| Female | 14 (29.79%) | |
| Region | North America | 16 (34.04%) |
| Europe | 13 (27.66%) | |
| Asia | 10 (21.28%) | |
| Oceania | 6 (12.77%) | |
| South America | 2 (4.26%) | |
| Age (years) | Median age | 72 (42,86) a |
| ≤60 | 6 (12.77%) | |
| 61-70 | 14 (29.79%) | |
| 71-80 | 20 (42.55%) | |
| ≥81 | 7 (14.89%) | |
| Type of cancer | Melanoma | 25 (53.19%) |
| Lung carcinoma | 12 (25.53%) | |
| Bladder urothelial cancer | 4 (8.51%) | |
| Renal-cell carcinoma | 2 (4.26%) | |
| Endometrial cancer | 1 (2.13%) | |
| Cervical cancer | 1 (2.13%) | |
| Intrahepatic cholangiocarcinoma | 1 (2.13%) | |
| NA | 1 (2.13%) | |
| Time to cutaneous toxicity (40) b | Median time (months) | 4(0.7,28) a |
| ≤2 | 13 (31.71%) | |
| 3-7 | 12 (29.27%) | |
| 8-11 | 6 (14.63%) | |
| 14-18 | 6 (14.63%) | |
| ≥20 | 4 (9.76%) | |
| Time to bullae (45) b | Median time (months) | 7.35 (0.7,32) a |
| ≤3 | 8 (17.78%) | |
| 3-6 | 12 (26.67%) | |
| 6-12 | 12 (26.67%) | |
| 14-18 | 6 (13.33%) | |
| ≥20 | 7 (15.56%) | |
| Time from BP diagnosis to pembrolizumab termination | Median time (months) | 0 (0,11) a |
| Whether to discontinue pembrolizumab or not | Yes | 39 (82.98%) |
| Not | 4 (8.51%) | |
| NA | 4 (8.51%) | |
| Comorbidities (10) b | Hypertension | 3 (30.00%) |
| Chronic renal insufficiency | 2 (20.00%) | |
| Skin diseases | 4 (40.00%) | |
| Type 2 diabetes | 3 (30.00%) | |
| Crohn’s disease | 1 (10.00%) | |
| Hypothyroidism | 1 (10.00%) | |
| Neurologic diseases | 1 (10.00%) |
BP, bullous pemphigoid; NA, not available.
a
Median (minimum, maximum).
b
Indicates the number of 47 patients for whom information on the particular parameter was provided.